Next preclinical toxicology & pharmacology of drugs developed for cancer patients, to#3, exploratory studies of CCR4 cart cells
Ended Awarded Last action
- Contract number
- HHSN26100003
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $626,266
Award facts
- Opportunity
-
- N02CM4700142 Solicitation number
- Preclinical toxicology of drugs developed for cancer patients Award Notice · Posted Jul 6, 2016
- Preclinical toxicology of drugs developed for cancer patients Award Notice · Posted Apr 4, 2014
- Contract value 100% obligated
- $626,265.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$91,999 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $238,571 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $479,694 |
About this award
The National Cancer Institute issued a $626,265.68 delivery order to IIT Research Institute on September 6, 2017, under the Toxicology of Drugs Developed for Cancer Patients IDIQ for exploratory studies of CCR4 CAR T cells and preclinical toxicology and pharmacology of cancer drugs, with ultimate completion on September 30, 2022.
Place of performance is Chicago, IL. The order carries cost-plus-fixed-fee pricing. IIT Research Institute is a non-profit contract research organization and wholly-owned subsidiary of Illinois Institute of Technology, operating as a specialized preclinical drug development and toxicology research provider to NIH institutes without set-aside designations.
Service Contract Inventory data for this order span FY2021–FY2022. In FY2022, the most recent reported year, the order invoiced $430,000 across 0.6 FTEs and 1,198 contractor hours at a derived government-paid rate of $359.12 per hour. IIT Research Institute self-performed all reported hours with no subcontractor engagement. Invoiced labor activity increased from 48 contractor hours in FY2021 (zero FTEs) to 1,198 contractor hours in FY2022, reflecting year-over-year scaling of preclinical research delivery.
Quick answers
Who was awarded contract HHSN26100003?
HHSN26100003 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on September 6, 2017.
How much is contract HHSN26100003 worth?
The government has obligated $626,266 on HHSN26100003.
Is contract HHSN26100003 an order under another contract?
Yes. HHSN26100003 is a delivery order under HHSN261201600015I, an indefinite delivery contract, on Toxicology of Drugs Developed for Cancer Patients.
Was contract HHSN26100003 competed?
The extent of competition for HHSN26100003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award